GCP Clinplus

What GCP Clinplus does

GCP ClinPlus (legal name: 普瑞盛（杭州）医药科技开发股份有限公司) is a China-headquartered international Contract Research Organization (CRO) founded in 2003, operating from Hangzhou with a US regional office in Cranbury, New Jersey, and additional offices in Beijing, Shanghai, Qingdao, and Guangzhou. The company provides end-to-end clinical research services, including Medical Affairs, Clinical R&D, Registration Affairs, Field Service (monitoring), Data Management/Biostatistics/Statistical Programming, Quality Assurance, Pharmacovigilance, and Medical Research Joint Center services. Therapeutic-area specialization spans oncology, cardiovascular, cell and gene therapy (CGT), ophthalmology, endocrinology, neurology, respiratory, infectious disease, and autoimmune indications, with stated execution of 200+ MRCTs and support for 220+ market-approved products across NMPA, FDA, and EMA.

The technology stack is anchored by two proprietary platforms: the Clinx Clinical Intelligence Platform (Clinx临研智能平台), an AI-powered platform for clinical data compliance and risk management, and the Dynamic Data Integration Platform for end-to-end data flow from collection through statistical analysis. The company maintains CDISC Platinum Member status with 12 years of submission experience and is certified in Medidata Rave, Coder, Builder, and RTSM systems.

The business model is project-based professional services revenue, offered via Full Service Outsourcing (FSO, end-to-end biometrics and clinical operations), Functional Service Provider (FSP, dedicated team extensions), and strategic consulting engagements. Go-to-market is direct enterprise field sales targeting global pharmaceutical companies, international biotech firms (especially those in-licensing Chinese assets), multinational pharma developing global+China integrated strategies, CGT developers, and Chinese pharma innovators. The company has served 500+ clients across 2,300+ trials with a 67%+ annual repeat order rate. Pricing is multi-year contract-based with free initial consultations, and the company claims 2-3x faster patient recruitment and 60-80% lower trial costs relative to US/EU markets as part of its value proposition.

Name

GCP Clinplus

Legal name

普瑞盛（杭州）医药科技开发股份有限公司

Website

https://gcp-clinplus.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

GCP ClinPlus is a China-based international CRO providing end-to-end clinical research services—including biometrics, regulatory affairs, monitoring, and CGT expertise—to global pharmaceutical, biotech, and cell-and-gene-therapy developers across Asia and North America.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Clinical research services
• Biostatistics programming
• Regulatory affairs
• Pharmacovigilance services
• Cell gene therapy

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Clinical Research Services: Full-service clinical trial management including medical affairs, clinical R&D, registration affairs, field service, data management, biostatistics, statistical programming, quality assurance, pharmacovigilance, and medical research joint center services. Revenue generated through project-based contracts with pharmaceutical and biotech companies.
2. Biometrics Services: Comprehensive biometrics services including data management, biostatistics, and statistical programming for clinical trials. Provides FSO (Full Service Outsourcing) and FSP (Functional Service Provider) solutions.
3. Cell & Gene Therapy (CGT) Services: Specialized clinical trial services for cell and gene therapy products, including CGT clinical studies across multiple indications (hematologic malignancies, solid tumors, genetic disorders)

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

GCP Clinplus is a China-based international Contract Research Organization (CRO) providing full-service clinical research services across the drug development lifecycle. Core offerings include Medical Affairs, Clinical Research & Development, Registration Affairs, Field Service (site monitoring), Data Management/Biostatistics/Statistical Programming, Quality Assurance, Pharmacovigilance, and Medical Research Joint Center partnerships. The company operates an integrated platform-plus-services model underpinned by its proprietary Clinx AI-powered clinical intelligence platform, serving therapeutic areas spanning oncology, cardiovascular, cell and gene therapy (CGT), ophthalmology, endocrinology, neurology, respiratory, infectious disease, and immunology.

Product overview

GCP ClinPlus is a Contract Research Organization (CRO) providing comprehensive clinical research services through an integrated platform-plus-services model. The core offerings include Medical Affairs, Clinical Research & Development, Registration Affairs, Field Service, Data Management/Biostatistics/Programming, Quality Assurance, Medical Research Joint Center, and Pharmacovigilance. The company operates the proprietary Clinx临研智能平台 (Clinx Clinical Intelligence Platform) and Dynamic Data Integration Platform as technology enablers. Services span Phase I-III clinical trials, Phase IV & NIS studies, Bioequivalence/PK/PD studies, Centralized Monitoring, and Non-Blind Monitoring. The company specializes in therapeutic areas including oncology, cardiovascular, cell and gene therapy (CGT), ophthalmology, endocrinology, neurology, respiratory, infectious disease, and immunology.

Differentiator

Problem solved

Functional benefit

Brands

• Clinx: Proprietary intelligent clinical research platform developed by GCP ClinPlus for clinical data compliance and management.

Products and services

• Medical Affairs (医学事务) Medical affairs services supporting clinical trial operations, providing strategic medical expertise and regulatory consultation for pharmaceutical and biotech clients.
• Clinical Research & Development (临床研发) Comprehensive clinical research and development services from early phase through commercialization, including Phase I-III trials, Phase IV & NIS studies, and bioequivalence/PK/PD studies for global pharmaceutical and biotech clients.
• Registration Affairs (注册事务) Regulatory registration affairs services for drug and device approvals with NMPA, FDA, and EMA, supporting multi-region submissions and bridging studies.
• Field Service (现场服务) On-site clinical trial monitoring and site management services ensuring trial quality and compliance across multiple research sites, including non-blind monitoring.
• Data Management, Biostatistics & Statistical Programming (数据管理、生物统计和统计编程) End-to-end biometrics services including clinical data management, biostatistics, and SAS programming supporting global regulatory submissions; offered via FSO (Full Service Outsourcing) and FSP (Functional Service Provider) models with a 200+ biometrics team.
• Quality Assurance Service (质量保障服务) Quality assurance services ensuring compliance with GCP, GMP, and international standards across clinical trial operations.
• Medical Research Joint Center (医研联合中心) Collaborative research center partnerships with leading hospitals (including 70+ transplant centers for cell therapy) for clinical trial execution, site management, and investigator engagement.
• Pharmacovigilance (药物警戒) Drug safety monitoring and pharmacovigilance services operating throughout the product lifecycle, including adverse event reporting and risk management.
• Clinx Clinical Intelligence Platform (Clinx临研智能平台) Proprietary AI-powered clinical research intelligence platform that serves as the compliance foundation for clinical data, enabling automated data programming, data cleaning, and basic process execution.
• Dynamic Data Integration Platform Proprietary platform for intelligent end-to-end management from data collection through statistical analysis, enabling real-time data monitoring and quality assurance.

Quantifiable outcome

• 67%+ customer repeat order rate
• +6 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• ProBio Inc.coreStrategic or Co-development Partner · 3 June 2026Strategic collaboration to accelerate Investigator-Initiated Trials (IITs) in China, combining ProBio's biologics and cell and gene therapy CDMO expertise with GCP ClinPlus's clinical trial execution capabilities and hospital network. The partnership aims to provide integrated, end-to-end clinical and development solutions for global biopharma companies, streamlining entry into China's clinical research ecosystem. Leverages ProBio's experience supporting over 40 IIT programs and GCP ClinPlus's track record spanning more than 80 CGT projects.
• FosunKite (Fosun Pharma)coreStrategic or Co-development Partner · 1 January 2025Co-development partnership for Yescarta CAR-T therapy specifically for the China market, leading to NMPA approval. Example of successful global-China integration model for CGT products.
• Janssen (Johnson & Johnson)coreStrategic or Co-development Partner · 1 January 2025Partnership with Legend Biotech through Janssen to develop Carvykti (CAR-T therapy), which received both FDA approval and Breakthrough Therapy Designation in China.

Scale indicators15 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Hangzhou Tigermed Consulting: China's largest publicly-traded clinical CRO, also headquartered in Hangzhou, providing full-service clinical trial solutions across Phase I-IV. Tigermed is GCP ClinPlus's most direct domestic competitor for global pharma seeking China clinical capabilities.
• WuXi Clinical (WuXi AppTec subsidiary): Major China-based clinical CRO with comprehensive clinical development services and global reach. WuXi Clinical competes directly with GCP ClinPlus for both Chinese innovator out-licensing work and Western pharma China entry mandates.
• Frontage Holdings: US-listed (with significant China operations) CRO offering clinical and bioanalytical services. Comparable in biometrics/CRO focus and cross-border China-US service capability, though with stronger bioanalytical laboratory footprint.
• Asymchem Laboratories: China-headquartered CDMO with growing clinical services capabilities. While primarily a CDMO, its clinical services expansion represents an adjacent competitor for integrated drug development contracts.

Broad incumbents

• IQVIA: World's largest CRO with extensive clinical operations globally including China. Competes for major pharma full-service outsourcing contracts and represents the global benchmark GCP ClinPlus must meet for tier-1 client wins.
• ICON plc: Top-3 global CRO providing full-service clinical development across all major therapeutic areas. Competes for the same global pharma client base that GCP ClinPlus targets for cross-border China-enabled studies.
• Labcorp Drug Development (formerly Covance): Global clinical CRO and central laboratory services provider with extensive Phase I-IV capabilities. Competes particularly in central lab and biometrics services where GCP ClinPlus also has presence.
• Parexel International: Major global CRO with strong Asia-Pacific presence, particularly in Japan and China. Competes for global pharma clinical outsourcing and offers comparable regulatory/biometrics services.
• Medpace Holdings: Mid-to-large global CRO focused on biotech sponsors, offering full-service clinical development. Competes for the same biotech client base, particularly for global MRCTs where China inclusion is sought.

Regional players

• Novotech (Novotech Health Holdings): Asia-Pacific focused CRO with strong China and Australia operations. Competes for biotech clients seeking Asia-led clinical development and represents an alternative regional player in the same value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/gcp-cmic-clinplus-co.-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GCP Clinplus